| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Commentary |
Allegheny University of the Health Sciences, Graduate Hospital, Philadelphia, Pennsylvania, USA
Correspondence: David H. Henry, M.D., Allegheny University of the Health Sciences-Graduate Hospital, 1840 South Street, 2nd Floor, Philadelphia, Pennsylvania 19146, USA. Telephone: 215-893-7520; Fax: 215-893-7461; e-mail: dhhenry{at}juno.com
About 50% of cancer patients develop anemia; this incidence rises dramatically in patients with more advanced cancer or in those receiving chemotherapy or radiation therapy. Since the late 1980s, recombinant human erythropoietin (rHuEPO) has provided a safe and effective option for treating cancer-related anemia and fatigue. However, only about 50% of patients treated with rHuEPO adequately respond to therapy.
In the chronic renal failure (CRF) population, true iron deficiency is the most common cause of an inadequate response to rHuEPO. Functional iron deficiency occurs when iron cannot be provided rapidly enough to meet the demands of rHuEPO-induced erythropoiesis, despite the presence of adequate bone marrow iron stores. It is hypothesized that functional iron deficiency can also occur in cancer patients receiving rHuEPO and may account for the lack of response in a proportion of the oncology population.
Studies in CRF patients have shown that the administration of i.v. iron can correct functional iron deficiency more effectively than oral iron and may improve rHuEPO response. Therefore, it is important to monitor iron status and to address either true or functional iron deficiency prior to and during rHuEPO therapy to optimize the effect of rHuEPO in cancer patients. Studies are currently under way to determine the role of i.v. iron in treating cancer-related anemia.
This article has been cited by other articles:
![]() |
L. Bastit, A. Vandebroek, S. Altintas, B. Gaede, T. Pinter, T. S. Suto, T. W. Mossman, K. E. Smith, and J. F. Vansteenkiste Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia J. Clin. Oncol., April 1, 2008; 26(10): 1611 - 1618. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Henry, N. V. Dahl, M. Auerbach, S. Tchekmedyian, and L. R. Laufman Intravenous Ferric Gluconate Significantly Improves Response to Epoetin Alfa Versus Oral Iron or No Iron in Anemic Patients with Cancer Receiving Chemotherapy Oncologist, February 1, 2007; 12(2): 231 - 242. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Stasi, S. Amadori, T. J. Littlewood, E. Terzoli, A. C. Newland, and D. Provan Management of Cancer-Related Anemia with Erythropoietic Agents: Doubts, Certainties, and Concerns Oncologist, August 1, 2005; 10(7): 539 - 554. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Auerbach, H. Ballard, J. R. Trout, M. McIlwain, A. Ackerman, H. Bahrain, S. Balan, L. Barker, and J. Rana Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized Trial J. Clin. Oncol., April 1, 2004; 22(7): 1301 - 1307. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Henry, P. Bowers, M. T. Romano, and R. Provenzano Epoetin Alfa: Clinical Evolution of a Pleiotropic Cytokine Arch Intern Med, February 9, 2004; 164(3): 262 - 276. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Henry The Evolving Role of Epoetin Alfa in Cancer Therapy Oncologist, February 1, 2004; 9(1): 97 - 107. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Weiss New Insights Into Erythropoietin and Epoetin Alfa: Mechanisms of Action, Target Tissues, and Clinical Applications Oncologist, December 1, 2003; 8(90003): 18 - 29. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |